Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.440 +0.720 (+100.00%)

Streaming Delayed Price Updated: 9:34 AM EDT, Apr 20, 2026 Add to My Watchlist

Price and Volume

Volume	124,814,948
Open	1.330
Bid (Size)	1.440 (12,900)
Ask (Size)	1.450 (1,800)
Prev. Close	0.7200
Today's Range	1.220 - 1.440
52wk Range	0.0661 - 3.250
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Top movers in Monday's pre-market session ↗

Today 8:30 EDT

Via Chartmill

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Today 7:15 EDT

From Clearmind Medicine Inc.

Via GlobeNewswire

Performance

YTD	-27.6%	-27.6%
1 Month	+118.2%	+118.2%
3 Month	-45.5%	-45.5%
6 Month	+34.6%	+34.6%
1 Year	+37.1%	+37.1%

More News

These stocks have an unusual volume in today's session ↗

April 17, 2026

Via Chartmill

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

April 16, 2026

Via Chartmill

These stocks are moving in today's session ↗

April 15, 2026

Via Chartmill

These stocks have an unusual volume in today's session ↗

April 15, 2026

Via Chartmill

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

April 15, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Top stock movements in today's session. ↗

April 14, 2026

Via Chartmill

These stocks are moving in today's session ↗

April 14, 2026

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

April 14, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

April 14, 2026

Via Chartmill

Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

April 14, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Discover the top movers in Friday's pre-market session. ↗

April 10, 2026

Via Chartmill

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

March 30, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

March 27, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

March 19, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

March 17, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

March 13, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

March 11, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

March 10, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

March 04, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

February 09, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

February 06, 2026

From Polyrizon Ltd.

Via GlobeNewswire

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

February 06, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

February 03, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?

Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.

What exchange does Clearmind Medicine Inc. - Common Shares trade on?

Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?

The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market

What is the current price of Clearmind Medicine Inc. - Common Shares?

The current price of Clearmind Medicine Inc. - Common Shares is 1.440

When was Clearmind Medicine Inc. - Common Shares last traded?

The last trade of Clearmind Medicine Inc. - Common Shares was at 04/20/26 09:34 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.